[
    [
        {
            "time": "",
            "original_text": "巨头联姻！云南白药入股上药！",
            "features": {
                "keywords": [
                    "云南白药",
                    "入股",
                    "上海医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "巨头联姻！云南白药入股上药！",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "一项大规模多中心临床研究表明：“清肺排毒汤”可有效降低新冠肺炎死亡风险；知名药企 重磅大品种过评丨贝壳日报",
            "features": {
                "keywords": [
                    "清肺排毒汤",
                    "新冠",
                    "死亡风险",
                    "药企",
                    "过评"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "一项大规模多中心临床研究表明：“清肺排毒汤”可有效降低新冠肺炎死亡风险；知名药企 重磅大品种过评丨贝壳日报",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药企销售费用年榜:恒瑞、步长等超80亿 复星医药市场费蝉联第一",
            "features": {
                "keywords": [
                    "销售费用",
                    "恒瑞",
                    "步长",
                    "复星医药"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药企销售费用年榜:恒瑞、步长等超80亿 复星医药市场费蝉联第一",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "强强联姻！云南白药斥资112亿入股上海医药",
            "features": {
                "keywords": [
                    "云南白药",
                    "上海医药",
                    "入股",
                    "112亿"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "强强联姻！云南白药斥资112亿入股上海医药",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药(02607.HK)：SPH5030片临床试验申请获得受理",
            "features": {
                "keywords": [
                    "上海医药",
                    "SPH5030",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)：SPH5030片临床试验申请获得受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "长春百科IPO获批复丨人福新药丨海正ANDA获批丨上海医药、恒瑞、石药一致性评价丨君实、恒瑞临床许可",
            "features": {
                "keywords": [
                    "IPO",
                    "批复",
                    "上海医药",
                    "恒瑞",
                    "石药",
                    "一致性评价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "长春百科IPO获批复丨人福新药丨海正ANDA获批丨上海医药、恒瑞、石药一致性评价丨君实、恒瑞临床许可",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "上海医药(601607.SH)：SPH5030片用于晚期实体瘤治疗临床试验申请获受理",
            "features": {
                "keywords": [
                    "上海医药",
                    "SPH5030",
                    "晚期实体瘤",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)：SPH5030片用于晚期实体瘤治疗临床试验申请获受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药：SPH5030片临床试验申请获受理",
            "features": {
                "keywords": [
                    "上海医药",
                    "SPH5030",
                    "临床试验",
                    "申请受理"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药：SPH5030片临床试验申请获受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "瑞信：维持上海医药(02607)“跑赢大市”评级 目标价降至20港元 机构下调估值",
            "features": {
                "keywords": [
                    "瑞信",
                    "上海医药",
                    "跑赢大市",
                    "目标价",
                    "下调估值"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "瑞信：维持上海医药(02607)“跑赢大市”评级 目标价降至20港元 机构下调估值",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "快讯 | 上海医药、云南白药及天津医药拟共建“中医药产业联盟”，上海医药宣布引入云南白药作为战略投资者、天津医药完成混改后首度三方合作",
            "features": {
                "keywords": [
                    "上海医药",
                    "云南白药",
                    "天津医药",
                    "中医药产业联盟",
                    "战略投资者",
                    "混改"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "快讯 | 上海医药、云南白药及天津医药拟共建“中医药产业联盟”，上海医药宣布引入云南白药作为战略投资者、天津医药完成混改后首度三方合作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "云南白药112亿入股上海医药，刚亏了8亿的云南白药想干啥？ 亏损",
            "features": {
                "keywords": [
                    "云南白药",
                    "上海医药",
                    "入股",
                    "112亿",
                    "亏损"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "云南白药112亿入股上海医药，刚亏了8亿的云南白药想干啥？ 亏损",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]